NEWS : CIMS Healthcare Excellence Awards 2017- Best Hospital Unit in Oncology & Individual Excellence in the field of Operations * Padmashree Dr. Ramakant Deshpande, Executive Chairman and Director of ACI, receiving an award for the Best Healthcare Entrepreneur at Global Awards for Excellence in Quality Management & Leadership * ACI DAYCARE-BORIVALI 4 Feb launching of centre by the hands of cabinet Minister Shree Vinod Tawde & sitting MP Shree Gopal Shetty * Click Here To Take Appointment!!! * We have Sucessfully performed 250 Robotic Surgery till date *
BLOG : Afatinib Superior to Erlotinin Liquid Biopsy gives 100% accuracy Head and Neck New Urinary Molecular Test

On February 26, 2016, the U.S. Food and Drug Administration (FDA) approved the mTOR inhibitor everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated, nonfunctional, neuroendocrine tumors of gastrointestinal or lung origin with unresectable, locally advanced, or metastatic disease. This is on the basis of the phase III RADIANT-4 trial, which doubled the median progression-free survival time of patients. At Asian Cancer Institute, Dr Nilesh Lokeshwar will be delighted to answer questions that you may have.

Left Menu Icon